FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SAN FRANCISCO, Feb. 28, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) of the April 10, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Synergy securities between September 5, 2017 and November 14, 2017 and suffered losses, contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SGYP
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
The Complaint charges Defendants with making false or misleading statements about the terms of a $300 million senior secured loan to Synergy from CRG Partners III L.P. More specifically, the Complaint charges Defendants falsely described this financing as non-dilutive to shareholders on September 5, 2017.
When Synergy filed the CRG loan agreement with the SEC on November 9, 2017, it revealed that the financing would likely be dilutive to shareholders. This news drove the price of Synergy shares down $0.25, or about 8.4%, to close at $2.72 on November 10, 2017.
On November 14, 2017, Synergy filed a prospectus for the issuance of nearly 22 million shares and warrants to purchase nearly 22 million shares. This news drove the price of Synergy shares down $0.14, or about 6.9% to close at $1.89 on November 15, 2017.
“We’re focused on the defendants’ statements about the financing’s impact on equity investors that, if false, damaged them,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Synergy Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
